Increased oxidative stress has an important role in asthmatic airway inflammation and remodeling. A potent methyl donor, S-adenosylmethionine (SAMe), is known to protect against tissue injury and fibrosis through modulation of oxidative stress. The aim of this study was to evaluate the effect of SAMe on airway inflammation and remodeling in a murine model of chronic asthma. A mouse model was generated by repeated intranasal challenge with ovalbumin and Aspergillus fungal protease twice a week for 8 weeks. SAMe was orally administered every 24 h for 8 weeks. We performed bronchoalveolar lavage (BAL) fluid analysis and histopathological examination. The levels of various cytokines and 4-hydroxy-2-nonenal (HNE) were measured in the lung tissue. Cultured macrophages and fibroblasts were employed to evaluate the underlying anti-inflammatory and antifibrotic mechanisms of SAMe. The magnitude of airway inflammation and fibrosis, as well as the total BAL cell counts, were significantly suppressed in the SAMe-treated groups. A reduction in T helper type 2 pro-inflammatory cytokines and HNE levels was observed in mouse lung tissue after SAMe administration. Macrophages cultured with SAMe also showed reduced cellular oxidative stress and pro-inflammatory cytokine production. Moreover, SAMe treatment attenuated transforming growth factor-β (TGF-β)-induced fibronectin expression in cultured fibroblasts. SAMe had a suppressive effect on airway inflammation and fibrosis in a mouse model of chronic asthma, at least partially through the attenuation of oxidative stress and TGF-β-induced fibronectin expression. The results of this study suggest a potential role for SAMe as a novel therapeutic agent in chronic asthma.
INTRODUCTION
Asthma, which is defined as chronic airway inflammation and airway hyper-responsiveness, affects approximately 300 million people worldwide. 1, 2 Most patients show a favorable response to inhaled corticosteroids (ICS); however, progressive respiratory symptoms and a decline in lung function are observed in some asthmatics. Airway remodeling, which consists of mucus gland hypertrophy, increased airway smooth muscle mass and subepithelial fibrosis, is one of the defining features of chronic asthma. To date, no asthma drug has showed satisfactory effects on airway remodeling. 3 Therefore, the development of novel drugs that target both chronic inflammation and fibrosis is an important unmet need in asthma management.
Oxidative stress due to the imbalance between oxidative forces and the antioxidant defense system is considered a critical factor in the induction of chronic asthma. Excess reactive oxygen species (ROS) are reported to enhance inflammatory cell recruitment, pro-inflammatory cytokine production and the accumulation of extracellular matrix proteins in the airway wall in several animal studies. 4, 5 Additionally, enhanced oxidative stress is significantly associated with decreased lung function, which is one of the important clinical features of severe asthma. [6] [7] [8] The precise mechanism underlying the induction of irreversible airway obstruction by excessive ROS has not been clarified. However, oxidative stress is known to augment airway remodeling by stimulating the production of transforming growth factor-β1 (TGF-β1), fibronectin and vascular endothelial growth factor during lung fibroblasts. [9] [10] [11] S-adenosylmethionine (SAMe) is a principal biological methyl donor and key mediator of glutathione and polyamine synthesis that has a crucial role in many biochemical processes. 12 The therapeutic effects of SAMe in acute liver injury and liver fibrosis were well demonstrated through many experimental models and clinical trials. [13] [14] [15] [16] These effects are known be related to reduced oxidative stress, the maintenance of mitochondrial function, regulation of the cell cycle and inhibition of various mediators that have important roles in the development of liver inflammation and fibrosis. 17, 18 Recently, several studies with SAMe have been conducted in various diseases, including lung fibrosis. [19] [20] [21] [22] [23] Therefore, it was conceivable that SAMe might have a role in the suppression of airway inflammation and reduction in airway remodeling. However, a therapeutic role for SAMe in asthma had not been investigated previously. Using an inhalational model of Aspergillus fumigatus-induced chronic asthma, we demonstrated anti-inflammatory and antifibrotic effects of SAMe on allergic airway inflammation, most likely through the reduction of oxidative stress and inhibition of TGF-β1 signaling pathway activation.
MATERIALS AND METHODS

Animals and treatments
Six-to-eight-week-old female BALB/c mice were maintained in a pathogen-free area. To generate the chronic asthma model, the mice were intranasally challenged twice a week for 8 weeks with 22 μg of chicken ovalbumin (OVA; Grade V; Sigma Chemical Co., St Louis, MO, USA) and 5 μg fungal protease (protease from Aspergillus melleus; Sigma). In the control group, phosphate-buffered saline was administered. The animals were divided into three groups as follows: sham, a low dose of SAMe (30 mg kg − 1 ; Sigma), and a high dose of SAMe (150 mg kg − 1 ). SAMe was administered daily with feedings for 8 weeks starting at day 0 ( Figure 1 ). All mice were killed at day 58, and lung tissue was obtained for histopathological examination. The animal experiments described in this study were approved by our Institutional Animal Care and No Endobronchial Lesion Use Committee.
Bronchoalveolar lavage (BAL) fluid analysis
Mice were anesthetized and a trachea was cannulated to prepare for the procedure. BAL was performed with 2 ml phosphate-buffered saline through a tracheal cannula. BAL fluid samples were centrifuged, and the cell pellets were resuspended. Total cell counts were enumerated and differential cell counts were determined in a cytospin sample stained with Diff-Quick (Sysmex. Hyogo, Japan).
Histopathological evaluation
For histopathological examination, lungs were fixed in 10% neutralbuffered formalin for 24 h, embedded in paraffin wax, cut into 4-μm-thick sections and stained with hematoxylin and eosin (H&E). The degree of lung tissue inflammation was scored on a scale of 0-4 (0: none, 1: minimal, 2: mild, 3: moderate, and 4: marked). Additionally, periodic acid-Schiff (PAS) was used to identify mucus production, and Masson's trichrome staining was used to detect lung fibrosis.
Cell culture
Peribronchial and axillary lymph nodes (LNs) were used to determine various cytokine levels in the animal model. These were obtained aseptically and trimmed of excess fat. The nodes were homogenized with a 25-gauge syringe tip to obtain a single-cell suspension that was then washed twice in phosphate-buffered saline and centrifuged at 1500 g for 10 min at 4°C. Cell pellets were resuspended in RPMI 1640 (Welgene, Daegu, Korea) with 10% fetal bovine serum and 1% penicillin/streptomycin (Welgene). Cell suspensions were dispended into a 48-well plate, with each well receiving 4 × 10 5 cells in 0.5 ml of media. The cells were stimulated with 500 μg ml − 1 of OVA per well, and the supernatants were harvested 72 h after stimulation. To evaluate the underlying mechanisms of SAMe function, human macrophage (U937) and fibroblast (MRC5) cell lines were used. U937 cells were cultured in RPMI 1640 with 10% fetal bovine serum and 1% penicillin/streptomycin to 90% confluency. Cell suspensions were dispended into 100-mm culture dishes (Corning, Tokyo, Japan) at a density of 5 × 10 6 cells/dish and pretreated with 10 ng ml − 1 of phorbol myristate acetate (Invivogen, San Diego, CA, USA) for 24 h. After 24 h, 75 μM SAMe was added, and cells were maintained for another 24 h. The cells were then resuspended in a 48-well plate, with each well receiving 1 ml of medium containing 1 × 10 5 cells. The cells were stimulated with either 10 μg ml − 1 lipopolysaccharide (LPS; Sigma) or 10 μg ml − 1 DerP extract (Yonsei University, Seoul, Korea) for 24 h after SAMe treatment.
MRC5 cells were cultured in Minimum Essential Medium (Welgene) with 10% fetal bovine serum (Gibco, Grand Island, NY, USA), 1% penicillin/streptomycin and 1 mM sodium pyruvate (Welgene) to 90% confluency. The MRC-5 cells were seeded at a density of 2 × 10 5 cells per plate in a 60-mm dish and incubated overnight. After a 10-μM SAMe pretreatment, the cells were stimulated with 5 ng TGF-β1 (R&D Systems, Minneapolis, MN, USA) for 24 h.
Enzyme-linked immunosorbent assay
Cytokine concentrations were measured from mice lung-draining LN culture supernatants (described in the 'In vitro culture' section) and U937 cell culture supernatants. All cytokines in this study, including interleukin (IL)-4, IL-5, IL-6, IL-10, IL-13, IL-17, interferon (IFN)-γ and TGF-β1, were measured with Duoset ELISA Development Kits (R&D Systems) according to the manufacturer's instructions.
ROS detection by fluorescence plate reader
U937 cells were dispended into a 96-well plate at a density of 2 × 10 5 per well in 0.1 ml media and pretreated with or without SAMe for 24 h. Next, the cells were treated with 100 μM hydrogen peroxide and stained with 5 μM 2′,7′-dichlorofluorescein (Abcam, Cambridge, UK) for 30 min. The stained cells were assessed in a fluorescent plate reader (Perking Elmer-Wallac 1420 Victor 2 Multilabel plate reader, Perkin Elmer, MA, USA). 
Immunoblot analysis
Mouse lung tissue and MRC5 cells from each experiment were lysed in lysis buffer containing protease inhibitors on ice for 20 min. The lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (GE Healthcare, Amersham, UK). The following primary antibodies were used: anti-4-hydroxyl-2-nonenal (anti-HNE; Alpha Diagnostic, San Antonio, TX, USA), anti-β-actin (Bioworld, Dublin, OH, USA), antifibronectin (Abcam), anti-SMAD3, anti-phosphoSmad3 (S423/S425), anti-JNK (anti-c-Jun N-terminal kinase), anti-phospho-JNK (Thr183/Tyr185), anti-ERK (anti-extracellular signal-regulated kinase), and anti-phospho-ERK (Tyr204). All secondary antibodies were purchased from Bethyl Laboratories (Montgomery, TX, USA). The protein bands were detected with an enhanced chemiluminescence ()solution (GenDEPOT, Barker, TX, USA).
Statistical analysis
The results were expressed as the means ± s.e.m. and analyzed with the one-way analysis of variance component of the Kruskal-Wallis H-test according to their distribution normality using the SPSS software program version 18.0 (SPSS Inc., Chicago, IL, USA). A P-valueo0.05 was considered to be statistically significant.
RESULTS
SAMe attenuates allergic airway inflammation, airway fibrosis, lung oxidative stress and the production of various cytokines in a murine model of chronic asthma First, to verify whether the chronic inflammatory features were well reflected in our mouse model of chronic asthma in this study, we compared the histopathological findings from the current study to those from our previous studies that used a mouse model of conventional acute asthma. Briefly, the conventional acute asthma model was generated via intraperitoneal injections of 20 μg of chicken OVA with 100 μl alum on days 0 and 14 for sensitization, followed by inhalation challenges with 5% OVA on days 21, 22 and 23 for 30 min. 24 The mouse model of chronic asthma that was utilized in this study, which was challenged with a fungal protease and OVA for a period of 8 weeks, produced markedly increased mucus in the airway epithelium, as determined by PAS staining. Additionally, subepithelial collagen deposition was significantly increased in the chronic asthma mouse model compared with that in conventional acute asthma mouse models that were utilized in previous studies (Figures 2a and b) .
Next we compared the histological feature changes after SAMe administration in the mouse model of chronic asthma. In the H&E-stained lung sections in the chronic asthma model, peribronchial and perivascular cell infiltration and alveolar and vascular congestion were significantly increased compared with the control mice. After SAMe treatment, the magnitude of these parameters decreased remarkably compared with the untreated asthmatic group. SAMe suppressed airway inflammation in a dose-dependent manner (Figures 3a and b) . The results of the BAL fluid analysis revealed that the SAMe treatment led to a significant decrease in the number of total BAL cells and in each of the cell types evaluated with the differential cell count, including eosinophils (Figures 3c and d) . However, the PAS stain showed no significant difference in mucus cell hyperplasia and the areas of acidic mucus production between the SAMe-treated and untreated asthmatic mice (Figures 4a and b) . Subepithelial collagen deposition was measured, and the SAMe-treated lung tissue was found to have a markedly ameliorated degree of collagen deposition in a dose-dependent manner (Figures 4c and d) . Additionally, the SAMe-treated asthmatic mice showed lower levels of HNE, a representative marker of lipid peroxidation, in their lung tissue (Figures 5a and b) .
Several cytokines were measured from lung-draining LNs and lung tissues. In the lung-draining LNs, the IL-5, IL-13 and IL-10 levels were increased in asthmatic mice, whereas IFN-γ levels were not detected. After SAMe administration, all of the cytokine levels were markedly reduced ( Figure 6 ). The results of the cytokine levels measured in the lung tissues that were obtained from each study group showed a similar tendency to those in the LN cultures. The IFN-γ levels in the lung tissue were also decreased after SAMe treatment, although there was no statistical significance (Supplementary Figure S1) . However, in the BAL fluid analysis, cytokine levels were below the detectable range (data not shown).
SAMe reduces the production of various inflammatory mediators and oxidative stress in cultured human macrophages A marked increase in the production of cytokines, such as IL-6 and TGF-β1, was observed in LPS or house dust mite (HDM) extract-stimulated U937 cells compared with the control group. After SAMe treatment for 24 h, the cytokine levels were significantly reduced (Figures 7a and b) . Next the magnitude of ROS production after hydrogen peroxide stimulation was serially measured. The results showed significantly decreased ROS levels in the SAMe-treated U937 cells at each time point. These antioxidative effects were most prominent within 15 min of stimulation (Figure 7c ).
SAMe decreases TGF-β1-induced fibronectin expression by blocking Smad3, ERK and JNK phosphorylation in human fibroblasts
We next confirmed that SAMe significantly reduced TGF-β1-induced fibronectin expression in the human fibroblast cell line, MRC-5 (Figures 8a and b) . To elucidate the underlying signaling pathway from the SAMe effects, we evaluated the expression of TGF-β1-induced Smad3 phosphorylated (p-Smad3) for the canonical pathway and phosphorylated JNK (p-JNK) and ERK (p-ERK) for the non-canonical pathway. In the MRC-5 cell culture experiments, the p-Smad3, p-JNK and p-ERK levels were highly expressed within 5 min of TGF-β1 stimulation, and they were diminished by 15 min. The p-Smad3 levels were maintained for more than 30 min. The SAMe pretreated MRC-5 cells showed reduced TGF-β1-induced p-Smad3, p-JNK and p-ERK expression levels (Figures 8c and d) .
DISCUSSION
In the current study, SAMe effectively suppressed both airway inflammation and airway remodeling in a murine model of chronic asthma. The results revealed that SAMe reduced airway inflammation, excessive oxidative-stress burden and airway fibrosis through inhibiting both Smad-dependent and independent TGF-β1 signaling pathways. These findings suggest that SAMe is potentially an attractive, novel therapeutic agent for controlling chronic asthma.
SAMe, a well-known biological methyl donor generated in the cytosol of every mammalian cell, is linked with several essential metabolic pathways. As a potent antioxidant, SAMe has shown to ameliorate tissue inflammation and fibrosis in multiple disease models. [19] [20] [21] 25 As studies on the pathogenesis of severe asthma improved our understanding of the disease, oxidative stress is now considered to be an important factor in the development of airway inflammation and remodeling. 9, 10, 26 Based on these facts, we evaluated the role of SAMe in an asthma disease model for the first time.
Consistent with previous research, the current study demonstrated that SAMe treatment effectively reduced tissue infiltration of inflammatory cells in the airway in a 
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dose-dependent manner. 17, 20, 22 Furthermore, we observed a decrease in eosinophilic inflammation, which is a hallmark of T helper type 2 (Th2) inflammation. Previous studies demonstrated that SAMe inhibited Th1-dominant inflammation through the suppression of cytokines, such as IL-6, IL-8, tumor necrosis factor-α, and IFN-γ. 20, 22, 25 In this study, we identified a significant decrease in not only IFN-γ but also Th2 cytokines, such as IL-5 and IL-13 after SAMe treatment. Taken together, the results of this study support the hypothesis that SAMe generally attenuates airway inflammation via suppression of the Th2 immune response as well as Th1 inflammation.
Interestingly, the levels of IL-10, which is regarded as an anti-inflammatory cytokine, were increased in chronic asthma model and then reduced after SAMe administration. It was reported that IL-10 levels are decreased in asthma and that this phenomenon is associated with a reduction in IL-10-producing regulatory T cells. Additionally, our finding is opposite of what was observed in LPS-induced RAW mouse macrophages. [27] [28] [29] However, a reduction in IL-10 levels after SAMe treatment was also shown in a recent report by Li et al., 22 in which SAMe inhibited IL-10 expression in colon cancer cells. TGF-β, which is a pleiotropic cytokine with immunomodulatory property, was reported to induce IL-10 secretion from macrophages or regulatory T cells in several studies. [30] [31] [32] Therefore, we speculate that the decreased IL-10 levels in our chronic asthma model was associated with decreased TGF-β, as we observed a reduction of TGF-β in LPS/HDM-stimulated macrophages after SAMe treatment. Further studies are needed to clarify the exact mechanism.
We also observed that SAMe significantly inhibited the levels of IL-6 and TGF-β in LPS/HDM-stimulated macrophages. Previous studies demonstrated that decreased IL-6, tumor necrosis factor-α and TGF-β levels were associated with an anti-inflammatory, antifibrotic response following SAMe administration. 22, 23, 25, 33 Although asthma is typically a Th2 immunity-dominant disease, the underlying mechanism of asthma is much more complex than the simple Th2 paradigm. Cytokines, such as IL-6 and TGF-β, are involved in naive T-cell differentiation into Th17 cells, which is thought to induce neutrophil airway inflammation, a hallmark of severe asthma. 34 Moreover, TGF-β is one of the main mediators involved in airway remodeling in the asthmatic lung. 26 In the current study, SAMe produced an inhibitory effect on subepithelial collagen deposition, one of the key features of airway remodeling, which consists of airway fibrosis and mucus hypersecretion. Airway inflammation itself is a well-known causative factor of airway fibrosis, and our study focused on this aspect; however, it should also be kept in mind that airway fibrosis is not a simple consequence of inflammation, but a distinctive process that occurs in the asthmatic airway. [35] [36] [37] TGF-β is a profibrotic cytokine and has an essential role in airway fibrosis. TGF-β is known to signal primarily via intracellular Smad proteins, but several non-Smad signaling cascades exist, including the mitogen-activated protein kinase-ERK, JNK and p38 pathways. 38, 39 We found that SAMe reduced TGF-β1-induced phosphorylation of Smad3, JNK and ERK in cultured fibroblasts. Our results suggest that SAMe may reduce airway fibrosis by inhibiting both Smad-dependent and -independent TGF-β1 signal pathways. However, a recent study has reported inconsistent results that SAMe exhibited antifibrotic effects by suppressing TGF-β1-stimulated Sp1-ERK1/2 coupled elements, and not by the Smad-associated pathway, in a liver fibrosis model. 33 The exact mechanism underlying the SAMe-induced antifibrotic effect is still unclear; further research is definitely needed. To the contrary, SAMe showed no effect on mucus hypersecretion in this study, despite the decreased levels of IL-13, which is well known to induce mucus production. 40 Previously, Chu et al. 41 reported enhanced expression of TGF-β2, but not of TGF-β1, in asthmatic bronchial epithelial cells, which suggests that TGF-β2 is more likely to be involved with mucus hyperproduction. To clarify the underlying mechanism of the differential effect of SAMe on each airway remodeling component, further studies should be carried out. Consistent with results from previous studies, 17, 21, 23, 25 our study also showed an antioxidative capacity for SAMe in lung tissue of asthmatic mice and in vitro experiments using human macrophages. Oxidative stress is known to have a critical role in the initiation and aggravation of inflammation as well as airway remodeling. 42 Interestingly, it was reported that oxidative stress aggravates Th2-skewed inflammation. 43 These results suggest that the reduction of oxidative stress might be more effectively suppressed during Th2-dominant inflammation than other types of inflammation. It is conceivable that the anti-inflammatory and antifibrotic effects of SAMe in this study may be attributed to the antioxidant capacity of SAMe by modulating the overall inflammatory response, especially Th2-dominant inflammation. Nevertheless, we did not separately assess the impact of oxidative stress on Th2 inflammation. To clarify this issue, further studies are warranted.
In the current study, we assessed the therapeutic role of SAMe in chronic airway inflammation and remodeling. A. fumigatus is a potent indoor fungal allergen and a number of previous studies demonstrated that intranasal inhalation of aerosolized A. fumigatus allergen significantly enhances persistent airway hyper-reactivity, mucus cell hyperplasia and peribronchial collagen deposition, which are major features of chronic allergic airway disease. 44, 45 Thus we developed a chronic asthma model that included fungal allergen inhalation, which mimicked chronic inflammation and fibrosis much better than our conventional acute asthma model, and confirmed the therapeutic effect of SAMe.
In summary, to the best of our knowledge, our present study is the first to demonstrate a suppressive effect of SAMe on airway inflammation and remodeling in an experimental model of chronic asthma. The observed anti-inflammatory and antifibrotic effects might have been mediated by reduced oxidative stress. Our findings suggest a potential benefit of SAMe as a novel therapeutic drug that targets both airway inflammation and remodeling in chronic asthma. Importantly, SAMe has the advantage of currently being in use with no safety concerns.
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